BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 20495085)

  • 1. Genetic/familial high-risk assessment: breast and ovarian.
    Daly MB; Axilbund JE; Buys S; Crawford B; Farrell CD; Friedman S; Garber JE; Goorha S; Gruber SB; Hampel H; Kaklamani V; Kohlmann W; Kurian A; Litton J; Marcom PK; Nussbaum R; Offit K; Pal T; Pasche B; Pilarski R; Reiser G; Shannon KM; Smith JR; Swisher E; Weitzel JN;
    J Natl Compr Canc Netw; 2010 May; 8(5):562-94. PubMed ID: 20495085
    [No Abstract]   [Full Text] [Related]  

  • 2. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
    Shulman LP
    Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN.
    Blanco A; Graña B; Fachal L; Santamariña M; Cameselle-Teijeiro J; Ruíz-Ponte C; Carracedo A; Vega A
    Clin Genet; 2010 Feb; 77(2):193-6. PubMed ID: 19930417
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology.
    Allain DC
    J Mol Diagn; 2008 Sep; 10(5):383-95. PubMed ID: 18687797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA screening.
    Med Lett Drugs Ther; 2007 Nov; 49(1274):93-4. PubMed ID: 18007543
    [No Abstract]   [Full Text] [Related]  

  • 6. BRCA1 and BRCA2 mutations in breast and ovarian cancer syndrome: reflection on the Creighton University historical series of high risk families.
    Sinilnikova OM; Mazoyer S; Bonnardel C; Lynch HT; Narod SA; Lenoir GM
    Fam Cancer; 2006; 5(1):15-20. PubMed ID: 16528604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.
    Rajagopal PS; Nielsen S; Olopade OI
    JAMA Netw Open; 2019 Aug; 2(8):e1910142. PubMed ID: 31434110
    [No Abstract]   [Full Text] [Related]  

  • 8. Further development and evaluation of a breast/ovarian cancer genetics referral screening tool.
    Bellcross C
    Genet Med; 2010 Apr; 12(4):240. PubMed ID: 20395744
    [No Abstract]   [Full Text] [Related]  

  • 9. Management updates for women with a BRCA1 or BRCA2 mutation.
    Nusbaum R; Isaacs C
    Mol Diagn Ther; 2007; 11(3):133-44. PubMed ID: 17570734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
    Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
    Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [What attitude to women at high risk of breast cancer?].
    Livon D; Moretta J; Noguès C
    Presse Med; 2019 Oct; 48(10):1092-1100. PubMed ID: 31706893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hereditary breast and ovarian cancers.
    Herman LM;
    JAAPA; 2008 May; 21(5):18, 21. PubMed ID: 18556884
    [No Abstract]   [Full Text] [Related]  

  • 14. Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations.
    Wood ME; Garber JE; Isaacs C; Masood S; Bedrosian I; Tung N; Chun J; Schnabel FR; Arun BK;
    Breast J; 2019 Jul; 25(4):575-577. PubMed ID: 31280501
    [No Abstract]   [Full Text] [Related]  

  • 15. [Familial breast cancer, ovarian cancer].
    Inoue M
    Nihon Rinsho; 2006 Jun; Suppl 2():366-70. PubMed ID: 16817423
    [No Abstract]   [Full Text] [Related]  

  • 16. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.
    Moreno L; Linossi C; Esteban I; Gadea N; Carrasco E; Bonache S; Gutiérrez-Enríquez S; Cruz C; Díez O; Balmaña J
    Clin Transl Oncol; 2016 Oct; 18(10):981-7. PubMed ID: 26742938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Genetic testing in patients at risk for carcinoma of the breast].
    Kiechle M
    Dtsch Med Wochenschr; 2006 Oct; 131(43):2420-2. PubMed ID: 17054060
    [No Abstract]   [Full Text] [Related]  

  • 18. Hereditary breast cancer and genetic counseling in young women.
    Brunet J
    Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():7-9. PubMed ID: 20711663
    [No Abstract]   [Full Text] [Related]  

  • 19. Introduction to epidemiology of breast and ovarian cancers.
    Adaniel C; Kirchhoff T
    Ann Oncol; 2013 Nov; 24 Suppl 8():viii61-viii62. PubMed ID: 24131972
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.